BGMS
NASDAQ · Biotechnology
Bio Green Med Solution Inc
$0.90
-0.03 (-3.23%)
BGMS News30 articles
Bio Green Med Stock Surges 170% Pre-Market on All-Stock Future NRG Deal, Massive Dilution Ahead
Bio Green Med shares soared nearly 170% pre-market on an all-stock deal to buy Future NRG, but existing holders will own under 1% of the combined firm, raising dilution concerns.
Alamar Biosciences Stock Jumps 31% on Strong Consumables Growth
Alamar Biosciences (ALMR) shares soared 31% after Q2 revenue surged 82%, fueled by consumables sales that lifted gross margins and strengthened the recurring revenue outlook.
Ensysce Biosciences Stock Jumps 48% Premarket, Nasdaq Compliance Still Elusive
Ensysce Biosciences (NASDAQ:ENSC) shares jumped 48% in premarket trading, yet the stock remains 141% below the $1 minimum bid price required by Nasdaq. The compliance window begins August 11.
Gossamer Bio Surges on FDA Filing Update; Cash Covenant Looms
Gossamer Bio shares surged 46% on FDA feedback supporting its seralutinib NDA filing. Cash covenant and dilution risks persist.
Gossamer Bio Stock Jumps on FDA Filing Update, but Cash and Dilution Risks Remain
Gossamer Bio shares surged after an FDA filing update, but cash concerns and potential dilution continue to weigh on the stock.
Danaher's 50% Rebound Faces $100M Bioprocessing Deferral Hurdle
Danaher shares rebounded 50% from a post-earnings drop, but a $100 million bioprocessing revenue delay to 2027 tests the recovery.
Advanced Biomed Surges 74.6% After Terminating $25M Equity Facility
Shares of Advanced Biomed (ADVB) jumped 74.6% after the company terminated a $25 million equity facility, removing overhang of potential dilution.
Danaher Plunges 11% as Biotech Growth Disappoints, Triggering Valuation Reset
Danaher shares dropped 11% after its biotech segment underperformed expectations, leading to a valuation adjustment. Full-year core growth guidance was narrowed to 3%-4%.
Danaher Tumbles 11% as Biotech Growth Disappoints, Triggering Valuation Reset
Danaher shares plunged 11% on Tuesday after biotech growth fell short of expectations, prompting a sharp valuation reset even as quarterly revenue and earnings topped forecasts.
Danaher Shares Plunge 14% on Reduced Growth Forecast and Bioprocessing Gap
Danaher (DHR) stock dropped 14% after the company slashed its 2026 core-revenue growth forecast to 3%-4%, citing a bioprocessing order-to-revenue gap that overshadowed a quarterly earnings beat.
Iovance Biotherapeutics Shares Surge 18% as Amtagvi Sales Targets Come into Focus
Iovance Biotherapeutics (IOVA) shares climbed 18.2% last week as investors eye the ambitious sales targets for its cancer therapy Amtagvi.
ImmunityBio Faces Key Warrant Expiry Test on July 24 After Friday Rebound
ImmunityBio (NASDAQ:IBRX) faces a crucial warrant expiry on July 24, with up to 6.4 million shares potentially exercised, testing trading liquidity after a Friday rebound.
Iovance Biotherapeutics Soars 18% as Amtagvi Sales Target Nears
Iovance Biotherapeutics (IOVA) shares jumped 18% as investors focus on the upcoming sales test for Amtagvi, with second-quarter revenue guidance of $86-$88 million.
Iovance Biotherapeutics Soars 18% on No News, Rally Matches Cash Balance
Iovance Biotherapeutics (NASDAQ:IOVA) shares surged 18% to $4.645, adding ~$319M in market value, matching its cash position. The rally occurred without any new company news, suggesting short covering.
Biotech Sector Hit by $15B Loss as Vertex, Ionis Stumble
Vertex and Ionis shares slumped after setbacks, erasing $14.8B in market cap. Crinetics, BridgeBio, and Vera gained $6.1B combined.
Virax Biolabs Surges 183% on Exclusive Fosun Supply Pact
Virax Biolabs shares surged 183% after its UK subsidiary inked an exclusive supply deal with Fosun Diagnostics for the ImmuneSelect line, covering six Southeast Asian countries.
Recursion Pharmaceuticals Rallies as Short Interest and Russell Flows Drive AI-Biotech Surge
Recursion Pharmaceuticals (RXRX) rose 4.7% to $3.98, driven by heavy short interest and Russell index flows. The stock's volume surged above average as the market focused on upcoming clinical catalysts.
Recursion Pharma Rallies Past Biotech ETFs; Insider Sales and Cash Position in Focus
Recursion Pharmaceuticals (RXRX) surged 8% in a four-session week, beating biotech ETFs. Filings show insider sales, while the company's $665M cash position and upcoming data updates remain key.
Regencell Bioscience Shares Slide 63% Below May Offering Price
Regencell Bioscience (NASDAQ:RGC) dropped 6.6% to $7.50, remaining 63.1% below its May offering price, despite a brief intraday rebound. Biotech ETFs gained.
Regencell Bioscience Surges But Still 60% Below May Offering Price
Regencell Bioscience (RGC) shares surged 31.9% on Wednesday, yet still trade 60.4% below the May direct offering price. The stark rebound underscores the volatility and fundamental challenges facing the pre-revenue biotech.
Generate Biomedicines Shares Reclaim IPO Price After Heavy Trading Week
Generate Biomedicines (GENB) surged 13.7% in a week, closing Friday at $16.47—above its $16 IPO price—with heavy volume and a $2.11B market cap, as sector momentum lifts biotech stocks.
ImmunityBio Volume Surges on Russell Index Changes; Monday Trading Key
ImmunityBio surged 11.8% on Friday with volume tripling its average, driven by Russell index reconstitution. Monday's trading will reveal if the spike holds.
ImmunityBio Jumps on Russell Index Rebalancing and High Valuation
ImmunityBio surged 9.2% to $8.51 as its market cap exceeded the Russell 1000 cutoff, drawing buyers ahead of index reconstitution.
Can-Fite BioPharma Surges on Japanese Patent Grant for Obesity Drug
Can-Fite BioPharma shares surged 17% premarket after Japan allowed a patent for Namodenoson in obesity, but the company's $6.61M market cap remains near the NYSE American delisting threshold.
Bio-Techne Jumps on Merck KGaA Cash Bid; Spread Signals Deal Risk
Bio-Techne shares jumped 19% on Merck KGaA's $73 cash offer, leaving a $2.83 spread as the deal awaits shareholder and regulatory approvals.
Iovance Biotherapeutics Stock Surges on $89.7 Million ATM Offering
Iovance shares rose 9.4% after launching an $89.65 million ATM stock sale, as investors balance dilution risks against the potential for accelerated Amtagvi revenue growth.
Landseed Secures $400K to Advance Sensor-Based Biodiversity Verification
Landseed raised $400,000 to develop AI sensors that verify ecological outcomes for biodiversity credits, targeting market trust issues.
Lunai Bioworks Shares Surge on Nasdaq Compliance Filing
Lunai Bioworks shares surged 80.88% after hours to $5.15 after Nasdaq confirmed compliance with the $1 minimum bid-price rule, averting delisting risk, though the company remains under a one-year panel monitor and has expressed substantial doubt about its ability to continue operations.
Regentis Biomaterials Shares Retreat After Record Surge on Withdrawal of Share Offering
Regentis Biomaterials shares dropped 27.66% premarket after a 506% surge driven by the withdrawal of a planned share offering, with investors focusing on upcoming surgeon training and funding concerns.
Theriva Biologics Surges on Phase 1 Cancer Data, But Risks Remain
TOVX surged 74.6% on Phase 1 VCN-01 data showing survival and biomarker signals in head-and-neck cancer, but the jump is not based on approval or revenue.